Manufacture of 5.5-KG cgmp mitragynine
Ended Awarded Last action
- Contract number
- 75N95019F00088
- Awardee
-
Curia Global Inc. UEI ELCNZCS8GEA3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,791,010
Award facts
- Opportunity
-
- N01TR172001 Solicitation number
- CRO Support for NCATS Drug Substance Development and Manufacture Award Notice · Posted Mar 1, 2016
- Contract value 83% obligated
-
- $2,791,010.00 Current, with exercised options
- $3,370,313.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Albany, NY 12212, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$19,515 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $15,550 | |
| Supplemental Agreement for work within scope | $215,020 | |
| Exercise an Option | $230,995 | |
| Supplemental Agreement for work within scope | $212,500 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $2,136,460 |
About this award
This federal contract award is for the manufacture of 5.5-kg of cGMP mitragynine, a drug substance, by Curia Global Inc. (doing business as Amri). The award, with a ceiling value of $3,370,313.00, was issued by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the Department of Health and Human Services. This is a delivery order under the CRO Support for NCATS Drug Substance Development and Manufacture indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. The contract has a period of performance through May 31, 2024 and does not have a set-aside designation. Curia Global is a leading contract development and manufacturing organization (CDMO) that provides a wide range of pharmaceutical research and development services to federal agencies, particularly the National Institutes of Health, through prime and subcontract awards.
Quick answers
Who was awarded contract 75N95019F00088?
75N95019F00088 was awarded to Curia Global Inc. by National Institute on Drug Abuse (National Institutes of Health) on August 22, 2019.
How much is contract 75N95019F00088 worth?
The government has obligated $2,791,010 on 75N95019F00088. Its potential value, with all options, is $3,370,313.
Which agency awarded contract 75N95019F00088?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95019F00088, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N95019F00088 an order under another contract?
Yes. 75N95019F00088 is a delivery order under HHSN271201700005I, an indefinite delivery contract, on CRO Support for NCATS Drug Substance Development and Manufacture.
Was contract 75N95019F00088 competed?
The extent of competition for 75N95019F00088 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award